Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkyePharma Stops Feasibility Study On Drug Delivery Systems With Dr Reddy’s

This article was originally published in PharmAsia News

Executive Summary

Mumbai - London-based specialized drug delivery technology company SkyePharma announced as part of its management statement Oct. 27 that the collaborative feasibility project with Dr Reddy's Labs has been stopped pending further assessment

You may also be interested in...



Diabetes Drug Of India’s Dr. Reddy’s Hits Danish Trial Firm Problems

A Danish company conducting a Phase III trial on a diabetes drug for India's Dr. Reddy's Laboratories has encountered financial problems, possibly delaying the drug's introduction. Rheoscience has the Indian drug maker's balaglitizone in trials as a treatment for Type 2 diabetes and the drug was considered ahead of Indian competitors with launching possible as early as 2011. If Rheoscience cannot finish the trials, its parent, Nordic Bioscience is considered likely to finish them. (Click here for more

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1134478

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel